Last reviewed · How we verify
continuous infusion of terlipressin
continuous infusion of terlipressin is a Small molecule drug developed by University of Roma La Sapienza. It is currently in Phase 2 development.
At a glance
| Generic name | continuous infusion of terlipressin |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- tachycardia
- diarrhea
- Energy increased
- decreased appetitie
- Hyponatremia
Key clinical trials
- Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation (NA)
- Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury (NA)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial (PHASE2)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial (PHASE3)
- Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation (NA)
- Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed (PHASE2, PHASE3)
- Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) (PHASE3)
- Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuous infusion of terlipressin CI brief — competitive landscape report
- continuous infusion of terlipressin updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI
Frequently asked questions about continuous infusion of terlipressin
What is continuous infusion of terlipressin?
continuous infusion of terlipressin is a Small molecule drug developed by University of Roma La Sapienza.
Who makes continuous infusion of terlipressin?
continuous infusion of terlipressin is developed by University of Roma La Sapienza (see full University of Roma La Sapienza pipeline at /company/university-of-roma-la-sapienza).
What development phase is continuous infusion of terlipressin in?
continuous infusion of terlipressin is in Phase 2.
What are the side effects of continuous infusion of terlipressin?
Common side effects of continuous infusion of terlipressin include tachycardia, diarrhea, Energy increased, decreased appetitie, Hyponatremia.